Last reviewed · How we verify
A-Phase: tirofiban; Z-Phase simvastatin
This is a combination therapy pairing tirofiban (a platelet glycoprotein IIb/IIIa inhibitor) with simvastatin (an HMG-CoA reductase inhibitor/statin) to provide dual antiplatelet and lipid-lowering effects.
This is a combination therapy pairing tirofiban (a platelet glycoprotein IIb/IIIa inhibitor) with simvastatin (an HMG-CoA reductase inhibitor/statin) to provide dual antiplatelet and lipid-lowering effects. Used for Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction), Secondary prevention of cardiovascular events in patients with hyperlipidemia.
At a glance
| Generic name | A-Phase: tirofiban; Z-Phase simvastatin |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Antiplatelet agent + HMG-CoA reductase inhibitor (combination therapy) |
| Target | Glycoprotein IIb/IIIa receptor (tirofiban); HMG-CoA reductase (simvastatin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Tirofiban blocks the final common pathway of platelet aggregation by inhibiting the glycoprotein IIb/IIIa receptor, preventing thrombotic events in acute coronary syndromes. Simvastatin reduces cholesterol synthesis and has pleiotropic anti-inflammatory and endothelial-protective effects. The combination targets both acute thrombotic risk and chronic atherosclerotic disease progression.
Approved indications
- Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)
- Secondary prevention of cardiovascular events in patients with hyperlipidemia
Common side effects
- Bleeding (minor and major)
- Thrombocytopenia
- Myalgia
- Elevated liver enzymes
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A-Phase: tirofiban; Z-Phase simvastatin CI brief — competitive landscape report
- A-Phase: tirofiban; Z-Phase simvastatin updates RSS · CI watch RSS
- Organon and Co portfolio CI